We apply insights and innovation at each stage of our business and utilize our internal capabilities and those of our partners around the world. The table below summarizes the status of our key programs for internal development or co-development.
We have an economic interest in potential future payments from GSK pursuant to its agreements with Innoviva, Inc. relating to certain respiratory programs, plus certain other programs that have been out-licensed or divested which do not require further economic investment by Theravance Biopharma.
*The information regarding the Trelegy Ellipta programs is based solely upon publicly available information and may not reflect the most recent developments under the programs.
Chronic Obstructive Pulmonary Disease
Complicated Skin and Skin Structure Infections
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Janus kinase inhibitor
Neurogenic Orthostatic Hypotension
Post-operative Gastrointestinal Dysfunction
The most advanced stage of clinical development that has been completed or is in process
Initial clinical safety testing into patients or healthy human volunteers, or studies directed toward understanding the mechanisms of action of the drug
Further clinical safety testing and preliminary efficacy testing in a limited patient population
Evaluation of clinical efficacy and safety within an expanded patient population
A marketing application has been submitted to a regulatory authority
Approved for marketing in one or more countries